The GLP-1 economy in five minutes: verified drug prices, and the business behind them.
The market for a drug that does not exist.
Eli Lilly is suing six companies for selling retatrutide, a drug no regulator anywhere has approved and that Lilly will not ask to sell until 2027. It already has sellers, customers and a price.
THE SKIM
- Eli Lilly is suing six companies over sales of retatrutide, a drug no regulator anywhere has approved and that Lilly will not ask to sell until 2027.
- Four of the six are peptide sellers, which sit outside the compounding rules the FDA spent this year tightening.
- Aspen now holds four approved semaglutide products in Canada and has sold none of them.
Eli Lilly is suing six companies for selling a drug that does not legally exist yet. Not a copy of one, and not a version mixed up from bulk powder. The drug itself, which no regulator on earth has approved for anybody.
The floor
THE FLOOR
United States
$149 USD/mo
Wegovy pill, NovoCare
Canada
C$88 CAD/mo
Apo-Semaglutide, Costco
Set a free alert and we email you the day one of these moves, or the day a drug that has never had a price gets one. Set an alert →
Cheapest verified price we hold per market, promotional and introductory offers excluded.
Every figure above, and every other price we hold, is on the price board with the date we checked it and the method we used.
Selling a drug that does not exist
THE BLACK MARKET: a drug nobody can legally sell already has sellers, customers and a price.
People are buying and injecting retatrutide right now. It is Lilly’s next obesity medicine, and it is in phase 3, the last stage of human testing before a company asks permission to sell. In Lilly’s own words, no medicine containing it “has yet been approved for human use by any regulatory agency in the world.” Lilly does not plan to ask the FDA until 2027.
On August 12, 2026, the company announced six lawsuits over illegal sales of it.
Look at who Lilly sued, because that is the finding. Four of the six sell research peptides: chemicals labelled “research use only” and sold as though nobody intends to put them in their body. One is a compounding pharmacy, a pharmacy that mixes drugs to order, which is legal in narrow circumstances. One is a medical spa. None is a telehealth prescriber.
That matters because the rules the FDA spent this year tightening are compounding rules. They reach pharmacies. They do not reach a chemical vendor who never claimed to be one.
Now read what Lilly did alongside the suits, which is the half that got skipped. Its announcement is a call on online platforms, payment companies and regulators to shut the market down. Lilly says it has referred more than 200 people and businesses to the FDA, the Justice Department, state attorneys general, law enforcement and licensing boards, and flagged more than 14,000 websites, advertisements and product listings across more than 100 countries. Those are the company’s own figures and nobody has audited them.
Suing sellers kills businesses. Cutting off listings and payment processing kills the channel. A company that believed six lawsuits would be enough would not need the second half.
Here is what makes this different from every enforcement story on this beat so far. Those were about copies of drugs people can already buy, where the legal hook is a patent or a compounding rule. Retatrutide offers neither. There is no approved product to copy, and no shortage to compound against.
The gray market used to form downstream of a launch. This one formed ahead of it.
Downticks
the week's business, in short
Four approvals, zero sales
Health Canada approved two more Aspen Pharmacare products on August 25, 2026, both Ozempic-label semaglutide pens. That gives Aspen four approved semaglutide products in Canada, under two names, and it has sold none of them. We re-checked the Drug Product Database, Health Canada’s public listing of every drug cleared for sale, on the evening of August 26: 22 product listings approved in Canada and unsold, none carrying a market date. Novo’s own twins have sat approved and unsold for 247 days, Apotex’s Sevmia for 58. It does not change generic pricing: Aspen is one manufacturer however many listings it files, and the price step waits on a third manufacturer actually reaching shelves.
Approved, and not for sale
The FDA granted tentative approval to Apotex’s generic semaglutide on April 10, 2026, per Apotex’s own announcement. Tentative approval means the agency has found the product acceptable but the company still cannot sell it. It is the first US generic semaglutide to get that far, and it happened four months ago with almost no coverage. What we cannot yet tell you is when it can actually launch, because that turns on patents and litigation we have not read at source.
The January handover
Two dates sit next to each other and run the wrong way round. Lilly’s Zepbound savings cards state “Card expires and savings end on 12/31/2026,” and Novo’s introductory self-pay pricing ends the same day. The next morning, January 1, 2027, Novo’s list price for Wegovy, Ozempic and Rybelsus falls to $675. List price is the sticker insurers negotiate against, and almost no individual pays it. Novo’s own release says the cut “does not impact other access efforts, including direct-to-patient, self-pay prices.” No successor to the expiring cash programs has been announced, which is not the same as none existing. We check on September 1.
Watching for
what moves next.
- The injunction ruling in Novo Nordisk’s case against Eli Lilly, day 8. Briefing closed on August 18, 2026, when Novo filed a reply and the last supporting declarations landed. We read the court’s public case file in full on August 26: 54 entries, no ruling. It can arrive any morning, decided on the papers with no hearing.
- Three sealed filings in that case, from August 24 and 25. One is a redacted document, which is often the public version of something previously filed under seal. The exact date Lilly revised the disputed television ad sits in two sealed declarations, and it is the longest-running open question we have. None of the three was readable as of August 26.
- September 1, and what replaces the cash programs. Lilly has announced no successor to the Zepbound card. Novo has ring-fenced self-pay out of its list-price cut. We said we would check, so the date is owed.
That is the brief. Same time Sunday.